<DOC>
	<DOCNO>NCT00002342</DOCNO>
	<brief_summary>To evaluate safety different dos dose regimen tecogalan sodium ( DS-4152 ) establish MTD different dosing schedule .</brief_summary>
	<brief_title>A Study Tecogalan Sodium</brief_title>
	<detailed_description>Patients receive intravenous DS-4152 infusion twice weekly 21 day , follow 2 week rest ; course may repeat . Patients undergo weekly follow-up . A punch biopsy obtain patient Kaposi 's sarcoma .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<criteria>Inclusion Criteria Patients must : Kaposi 's sarcoma plus HIV infection OR metastatic solid tumor . Life expectancy least 12 week . NO symptomatic AIDSdefining opportunistic infection within past 4 week . Recovered toxicity prior anticancer therapy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Leukemia lymphoma . Current gastrointestinal bleeding stool guaiac . Extensive bone metastases significant radiographic osteoporosis patient solid tumor . Active heart disease uncontrolled angina , uncompensated congestive heart failure , dysrhythmias require antiarrhythmic . Acute intercurrent infection genital herpes . Symptomatic known central nervous system involvement ( include brain metastasis ) unless stable therapy . Concurrent Medication : Excluded : Other anticancer therapy . Other investigational agent . Patients follow prior condition exclude : History acute chronic gastrointestinal bleeding inflammatory bowel disease . History myocardial infarction within past 6 month . Prior Medication : Excluded : Anticancer therapy within past 3 week ( 6 week nitrosourea mitomycin C ) . Investigational agent within past 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1996</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>tecogalan</keyword>
</DOC>